Skip to main content

Sterility

0
Pipeline Programs
3
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Ferring Pharmaceuticals
Ferring PharmaceuticalsArgentina - Buenos Aires
4 programs
hMG-HPN/A1 trial
hMG-HPN/A1 trial
hMG-HPN/A1 trial
hMG-HP/r-FSHN/A1 trial
Active Trials
NCT01330784Completed61Est. Sep 2008
NCT01331720Completed279Est. Jul 2010
NCT01331733Completed131Est. Mar 2009
+1 more trials
Merck & Co.
Merck & Co.RAHWAY, NJ
1 program
GnRH-ant protocolN/A
Fountain Therapeutics
1 program
GnRH-ant protocolN/A1 trial
Active Trials
NCT04026282Unknown888Est. Jul 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Fountain TherapeuticsGnRH-ant protocol
Ferring PharmaceuticalshMG-HP
Ferring PharmaceuticalshMG-HP
Ferring PharmaceuticalshMG-HP/r-FSH
Ferring PharmaceuticalshMG-HP

Clinical Trials (5)

Total enrollment: 1,410 patients across 5 trials

NCT04026282Fountain TherapeuticsGnRH-ant protocol

To Investigate the Cumulative Live Birth Rates Using GnRH Antagonist or Agonist Protocol for COS in ART Treatment

Start: Dec 2018Est. completion: Jul 2022888 patients
N/AUnknown
NCT01331720Ferring PharmaceuticalshMG-HP

Assessment of the Effectiveness and Tolerability of Ovarian Hyperstimulation

Start: Nov 2007Est. completion: Jul 2010279 patients
N/ACompleted
NCT01331733Ferring PharmaceuticalshMG-HP

Comparative Assessment of the Clinical Utility of Ovarian Stimulation With Menotropin Versus Menotropin Plus GnRH Antagonist

Start: Nov 2006Est. completion: Mar 2009131 patients
N/ACompleted
NCT01330771Ferring PharmaceuticalshMG-HP/r-FSH

Assessment of the Therapeutic Utility of r-FSH in Association With hMG-HP

Start: Oct 2006Est. completion: Sep 200851 patients
N/ACompleted
NCT01330784Ferring PharmaceuticalshMG-HP

Assessment of the Therapeutic Utility of hMG-HP

Start: Oct 2006Est. completion: Sep 200861 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.